Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozagrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 known ✓ | P24557 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozagrel SCHEMBL4211 | 1.00 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL36183 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL28049244 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL36182 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582827 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL1652693 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582828 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493930 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493936 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL27808192 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3558 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114411184-B | Electrochemical preparation method of ozagrel intermediate | 湖南大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-01-20 | — | — | US | claimed |
| WO-2025184468-A9 | MEASUREMENT OF URINE THROMBOXANE METABOLITES TO PREDICT SURVIVAL | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-16 | — | — | WO | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| CN-120152738-A | Methods of treating diseases using anti-IL 1RAP antibodies and antibody drug conjugates | 蓝鳍生物医药公司 | 2025-06-13 | — | — | CN | claimed |
| CN-119950740-A | Saponin conjugates | 萨普雷米科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119876097-A | Application of angiotensin converting enzyme 2 as target spot of medicine for treating traumatic brain injury | 济宁市第一人民医院(济宁市医学科学研究院) | 2025-04-25 | — | — | CN | claimed |
| CN-112203642-B | Pharmaceutical composition comprising a human hyaluronidase PH20 variant and a drug for subcutaneous injection | 阿特根公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119233826-A | Engineered antibodies via cellular receptors as molecular degrading agents | 耶鲁大学 | 2024-12-31 | — | — | CN | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061541-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-6028094-A | Agent for prevention and suppression of dry coughing caused by angiotensin converting enzyme inhibitors | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2000-02-22 | — | — | US | claimed |
| EP-0875254-A1 | AGENT FOR PREVENTION AND DEPRESSION OF DRY COUGHING CAUSED BY ANGIOTENSIN CONVERTING ENZYME INHIBITORS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-04 | — | — | EP | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |
| WO-1992006713-A1 | PHARMACEUTICAL COMPOSITION CONTAINING AN ACE INHIBITOR AND AN INHIBITOR OF THROMBOXANE A2 ACTIVITY FOR TREATING NEPHROPATHIES | FARMITALIA CARLO ERBA SRL (IT) | 1992-04-30 | — | — | WO | claimed |
| US-4925869-A | REACTIVATING ENZYME ACETYLCHOLINESTERASE INHIBITED BY LETHAL DOSE OF SOMAN | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | claimed |
| US-4908380-A | Substituted 1,3-dioxane ether derivative; thromboxane A2 inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | claimed |
| EP-0300675-A2 | Method for the improvement of cyclosporine therapy | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | claimed |